These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24824921)

  • 1. Clopidogrel: what is a cardiologist to do?
    Ford NF
    J Clin Pharmacol; 2014 Aug; 54(8):881-3. PubMed ID: 24824921
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it means.
    Hariharan S; Southworth MR; Madabushi R
    J Clin Pharmacol; 2014 Aug; 54(8):884-8. PubMed ID: 25044100
    [No Abstract]   [Full Text] [Related]  

  • 3. The clopidogrel-statin interaction.
    Tantry US; Jeong YH; Gurbel PA
    Circ J; 2014; 78(3):592-4. PubMed ID: 24521731
    [No Abstract]   [Full Text] [Related]  

  • 4. The clopidogrel conundrum.
    Bertino JS
    J Clin Pharmacol; 2014 Aug; 54(8):841-2. PubMed ID: 25044099
    [No Abstract]   [Full Text] [Related]  

  • 5. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
    Perry E
    Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
    [No Abstract]   [Full Text] [Related]  

  • 6. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 7. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
    George J; Doney A; Palmer CN; Lang CC
    Cardiovasc Ther; 2010 Jun; 28(3):135-8. PubMed ID: 20557312
    [No Abstract]   [Full Text] [Related]  

  • 9. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
    J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel and Genotyping.
    Ford NF
    J Invasive Cardiol; 2015 Aug; 27(8):E173-4. PubMed ID: 26232022
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel, CYP2C19, and a Black Box.
    Ford NF; Taubert D
    J Clin Pharmacol; 2013 Mar; 53(3):241-8. PubMed ID: 23381692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers.
    Liu M; Roden DM; Peterson JF
    Clin Pharmacol Ther; 2021 Oct; 110(4):860-862. PubMed ID: 33690885
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
    Ichikawa M; Takei Y; Hamasaki T; Kijima Y
    Circ J; 2015; 79(1):85-90. PubMed ID: 25744629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.
    Johnson DA; Chilton R; Liker HR
    Postgrad Med; 2014 May; 126(3):239-45. PubMed ID: 24918808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.
    ; ; ; Holmes DR; Dehmer GJ; Kaul S; Leifer D; O'Gara PT; Stein CM
    Circulation; 2010 Aug; 122(5):537-57. PubMed ID: 20585015
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors influencing platelet aggregation in patients with acute coronary syndrome].
    Mazurov AV; Ziuriaev IT; Khaspekova SG; Iakushkin VV; Sirotkina OV; Ruda MIa
    Ter Arkh; 2014; 86(9):83-9. PubMed ID: 25518511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.